Lung Cancer: Targets and Therapy

Professor Ou

Chao Family Comprehensive Cancer Center, Department of Medicine-Hematology/Oncology, University of California Irvine School of Medicine, United States

Professor Ou

Editor-in-Chief:  Professor Ou

Dr. Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served an an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.
Dr. Ou is one of the eight original phase 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publication in New Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou is on the scientific advisor board of TP Therapeutics which is developing the fourth generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer research and have been ad hoc reviewer for New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer for the American Society of Clinical Oncology annual meeting from 2016-2018.

Prof. Dr. Yang

Department of Internal Medicine and Dean, National Taiwan University College of Medicine, Taiwan

Prof. Dr. Yang

Editor-in-Chief: Professor Pan-Chyr Yang

Dr Yang currently is the Professor of the Department of Internal Medicine and Dean of the National Taiwan University College of Medicine. His major research interests are pulmonary and critical care medicine, lung cancer genomics, translational research and microarray gene expression technology. He is awarded as member of Academia Sinica in 2006 because of his contributions in promoting the translational research in lung cancer. 

Dr Yang is a pioneer and leader in pulmonary ultrasound diagnostics and therapeutics that have revolutionized the management of pulmonary diseases. His research group developed the method for detection and quantification circulating cancer cells in peripheral blood and to better predict the prognosis and response to treatment for lung cancer patients. His research group has discovered novel genes and pathways that associated with lung cancer pathogenesis and progression. They identified specific gene expression and microRNA signatures that can assist to predict the treatment outcome and may be beneficial for personalized therapy of lung cancer patients.

Dr Yang currently is the program director of the National Research Program for Biopharmaceuticals. He leads the translational biomedical research team to develop a fully integrated biopharmaceutical pipeline and set up comprehensive translational research platform as well as the biotech incubation centers, with the aim to strengthen biotech industry value chain and accelerate commercialization of biomedical research in Taiwan.